Current and evolving therapies for hepatitis C - PubMed (original) (raw)

Review

Current and evolving therapies for hepatitis C

D Moradpour et al. Eur J Gastroenterol Hepatol. 1999 Nov.

Abstract

Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Therapeutic options for hepatitis C are limited. Standard monotherapy with interferon-alpha leads to a sustained response in only 10-20% of patients. Recent studies have shown improved sustained response rates for the combination of interferon-alpha and ribavirin. Despite these improvements, more effective therapies are needed. A variety of alternative agents are currently being evaluated in clinical trials. Recent advances in the molecular virology of hepatitis C have identified specific antiviral targets such as the viral NS3 serine protease, the RNA helicase, and the RNA-dependent RNA polymerase. In addition, gene therapeutic strategies aimed at inhibiting HCV gene expression and replication as well as immunotherapeutic concepts aimed at enhancing the cellular immune response against HCV are being explored in various experimental systems. These and other novel antiviral strategies may complement the existing therapeutic modalities in the future.

PubMed Disclaimer

Similar articles

• [Hepatitis C].
  Moradpour D, Blum HE. Moradpour D, et al. Ther Umsch. 2004 Aug;61(8):493-8. doi: 10.1024/0040-5930.61.8.493. Ther Umsch. 2004. PMID: 15457965 Review. German.
• Hepatitis C: a concise review.
  Moradpour D, Wölk B, Cerny A, Heim MH, Blum HE. Moradpour D, et al. Minerva Med. 2001 Oct;92(5):329-39. Minerva Med. 2001. PMID: 11675577 Review.
• Hepatitis C: therapeutic perspectives.
  Cornberg M, Wedemeyer H, Manns MP. Cornberg M, et al. Forum (Genova). 2001 Apr-Jun;11(2):154-62. Forum (Genova). 2001. PMID: 11948360 Review.
• Future trends in managing hepatitis C.
  McHutchison JG, Dev AT. McHutchison JG, et al. Gastroenterol Clin North Am. 2004 Mar;33(1 Suppl):S51-61. doi: 10.1016/j.gtc.2003.12.001. Gastroenterol Clin North Am. 2004. PMID: 15081103
• Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
  Scott LJ, Perry CM. Scott LJ, et al. Drugs. 2002;62(3):507-56. doi: 10.2165/00003495-200262030-00009. Drugs. 2002. PMID: 11827565 Review.

Cited by

• In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus.
  Javed T, Ashfaq UA, Riaz S, Rehman S, Riazuddin S. Javed T, et al. Virol J. 2011 Jan 19;8:26. doi: 10.1186/1743-422X-8-26. Virol J. 2011. PMID: 21247464 Free PMC article.
• Hepatitis C virus infection and insulin resistance.
  Bose SK, Ray R. Bose SK, et al. World J Diabetes. 2014 Feb 15;5(1):52-8. doi: 10.4239/wjd.v5.i1.52. World J Diabetes. 2014. PMID: 24567801 Free PMC article. Review.
• Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes.
  Ciccaglione AR, Stellacci E, Marcantonio C, Muto V, Equestre M, Marsili G, Rapicetta M, Battistini A. Ciccaglione AR, et al. J Virol. 2007 Jan;81(1):202-14. doi: 10.1128/JVI.01011-06. Epub 2006 Oct 18. J Virol. 2007. PMID: 17050603 Free PMC article.
• Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A.
  He Y, Tan SL, Tareen SU, Vijaysri S, Langland JO, Jacobs BL, Katze MG. He Y, et al. J Virol. 2001 Jun;75(11):5090-8. doi: 10.1128/JVI.75.11.5090-5098.2001. J Virol. 2001. PMID: 11333890 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information